These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25281607)

  • 61. Role of TET2 mutations in myeloproliferative neoplasms.
    Pronier E; Delhommeau F
    Curr Hematol Malig Rep; 2012 Mar; 7(1):57-64. PubMed ID: 22200996
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.
    Fernandes de Oliveira Costa A; Olops Marani L; Mantello Bianco T; Queiroz Arantes A; Aparecida Lopes I; Antonio Pereira-Martins D; Carvalho Palma L; Santos Scheucher P; Lilian Dos Santos Schiavinato J; Sarri Binelli L; Araújo Silva C; Kobayashi SS; Agostinho Machado-Neto J; Magalhães Rego E; Samuel Welner R; Lobo de Figueiredo-Pontes L
    Front Immunol; 2022; 13():768592. PubMed ID: 36211444
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Myeloproliferative neoplasms and vascular diseases].
    Ikeda K
    Rinsho Ketsueki; 2022; 63(9):1107-1114. PubMed ID: 36198536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.
    Ahn JS; Li J; Chen E; Kent DG; Park HJ; Green AR
    Oncogene; 2016 Apr; 35(17):2235-46. PubMed ID: 26234675
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
    Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
    Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
    Rahman MF; Yang Y; Le BT; Dutta A; Posyniak J; Faughnan P; Sayem MA; Aguilera NS; Mohi G
    Nat Commun; 2022 Sep; 13(1):5347. PubMed ID: 36100596
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
    Saint-Martin C; Leroy G; Delhommeau F; Panelatti G; Dupont S; James C; Plo I; Bordessoule D; Chomienne C; Delannoy A; Devidas A; Gardembas-Pain M; Isnard F; Plumelle Y; Bernard O; Vainchenker W; Najman A; Bellanné-Chantelot C;
    Blood; 2009 Aug; 114(8):1628-32. PubMed ID: 19564637
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
    Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
    Nguyen-Khac F; Lesty C; Eclache V; Couronné L; Kosmider O; Andrieux J; Collonge-Rame MA; Penther D; Lafage M; Bilhou-Nabera C; Chapiro E; Mozziconacci MJ; Mugneret F; Gachard N; Nadal N; Lippert E; Struski S; Dastugue N; Cabrol C; Bernard OA;
    Genes Chromosomes Cancer; 2010 Oct; 49(10):919-27. PubMed ID: 20629097
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.
    Ikeda K; Ogawa K; Takeishi Y
    Fukushima J Med Sci; 2012; 58(2):91-100. PubMed ID: 23237864
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
    Gorantla SP; Dechow TN; Grundler R; Illert AL; Zum Büschenfelde CM; Kremer M; Peschel C; Duyster J
    Blood; 2010 Nov; 116(22):4600-11. PubMed ID: 20696946
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
    Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
    Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.
    Shi K; Zhao W; Chen Y; Ho WT; Yang P; Zhao ZJ
    J Hematol Oncol; 2014 Mar; 7():25. PubMed ID: 24646493
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice.
    Staehle HF; Heinemann J; Gruender A; Omlor AM; Pahl HL; Jutzi JS
    PLoS One; 2020; 15(2):e0228362. PubMed ID: 32017785
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
    J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.